Freedom Meditech | Date: 2011-11-07
Methods for spectroscopic analysis of biological tissues to classify an individual as diabetic or non-diabetic, or to determine the probability, progression or level of a disease or medical condition in an individual.
Freedom Meditech | Date: 2011-11-07
Apparatus and methods for spectroscopic analysis of biological tissues to classify an individual as diabetic or non-diabetic, or to determine the probability, progression or level of a disease or medical condition in an individual.
Freedom Meditech | Date: 2010-10-01
Freedom Meditech | Date: 2014-10-20
Freedom Meditech | Date: 2014-07-10
Downloadable computer software for use in the electronic storage of data collected from, and operational solely with, the trademark owners medical devices used in the detection of ocular degradation and instructional manual sold as a unit therewith.
Freedom Meditech | Date: 2013-03-13
Non-invasive medical devices used to detect ocular degradation that may cause blindness, cataract or other chronic disease due to elevated fluorescence in the lens of the eye measured against age related fluorescence. Printed reports for use by medical professionals relating to the responses of an eye to testing for ocular degradation.
Freedom Meditech | Date: 2012-05-29
Non-invasive medical device used to detect ocular degradations that may cause blindness, cataract or other chronic disease due to elevated fluorescence in the lens of the eye measured against age related fluorescence.
News Article | June 1, 2015
Freedom Meditech, a San Diego medical diagnostic company, said it has raised $4.8 million in a Series C financing round, bringing total venture funding to about $14 million in the nine years since the company was founded. The company also named John Gerace as CEO and as a member of the company’s board of directors. Gerace previously headed the applied sciences division of Carlsbad, CA-based Life Technologies, leaving at the beginning of 2014 as Waltham, MA-based Thermo Fisher Scientific completed its $13.6 billion acquisition of Life Technologies. Before that, Gerace served as vice president and general manager of the PCR systems business at Life Technologies. Gerace also recently co-founded San Clemente, CA-based Calabri Biosciences, which manages a portfolio of assets involved in wireless health diagnostics and monitoring. He is stepping in for founder Craig Misrach, who has served as CEO since Freedom Meditech was founded in 2006. Misrach remains involved, according to a spokesman for the company. He became vice-chairman of Freedom Meditech’s board in April 2014. In a recent statement, Freedom Meditech said Gerace would oversee all operations, build the management team and lead the company’s fundraising efforts to expand commercialization of the ClearPath DS-120, an ocular examination device. The technology uses a blue light to scan the eye, which causes the lens of the eye to emit light naturally, or autofluoresce. The system then measures the intensity of the autofluoresence, which has been correlated to the presence of sugar molecules in the eye lens. Higher autofluorescence measurements have been linked to higher levels of sugared proteins that accumulate from aging and the presence of systemic disease, the company says. The FDA cleared the device in 2013 as a non-invasive method that optometrists and ophthalmologists could use to screen their patients for diabetes. The device also has been cleared for sale in Europe and Canada. The company’s second product currently in development is a non-invasive ophthalmic glucose monitor that measures glucose levels in the eye for people with diabetes, to replace the finger-prick technologies currently in the market.
News Article | May 28, 2015
Freedom Meditech, Inc., a San Diego, California-based medical device company, raised $4.8 million in a Series C financing. The company intends to use the funds to advance its R&D programs. Led by newly named Mr. John Gerace as chief executive officer, Freedom Meditech focuses on the commercialization of novel non-invasive technologies for the detection of disease and management of patient health. The company’s first product, the ClearPath DS-120®, a non-invasive tool for the measurement of autofluorescence in the eye that has been cleared by the FDA, and has obtained the CE mark and a Canadian Establishment license is available for sale worldwide. The company’s second product currently in development is a non-invasive ophthalmic glucose monitor that measures glucose levels in the eye for people with diabetes, to replace the finger-prick technologies currently in the market. Freedom also has supporting research and development activities throughout the state of Ohio.